ReviewThe Yale journal of biology and medicine2023
The Molecular Mechanisms Involved in the Hypertrophic Scars Post-Burn Injury.
Review in The Yale journal of biology and medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- Angiotensin II as a Novel Biomarker in the Assessment and Prediction of Post-burn Hypertrophic Scarring: A Propensity Score-Matched Cohort Study.Aesthetic plastic surgery · 2026Article
- Biomimetic Dermal Substitutes for Skin Reconstruction: Advances in Scaffold Design, Biological Integration, and Clinical Performance.Journal of functional biomaterials · 2026Review
- Anti-fibrotic effects of evogliptin in fibroblasts derived from post-burn hypertrophic scars.Scientific reports · 2026Article
- Neuromodulation strategies in postburn care for pain rehabilitation and scar remodelling.Communications medicine · 2026Review
- Native Collagen for Surgical Wound and Scar Prevention-A Six-Case Clinical Series.Journal of clinical medicine · 2025Article
- Autologous Fat Granules Combined with PRP Treat Hypertrophic Scars Through TGF-β/Smad Signaling Pathway.Aesthetic plastic surgery · 2025Article
- Gut microbiota constituents may affect hypertrophic scarring risk through interaction with specific immune cells in a two-step, two-sample Mendelian randomization study.Scientific reports · 2025Article
- Leveraging Microneedles for Raised Scar Management.Polymers · 2025Review
- Slit1 Promotes Hypertrophic Scar Formation Through the TGF-β Signaling Pathway.Medicina (Kaunas, Lithuania) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scar formation is a normal response to skin injuries. During the scar-remodeling phase, scar tissue is usually replaced with normal, functional tissue. However, after deep burn injuries, the scar tissue may persist and lead to contractures around joints, a condition known as hypertrophic scar tissue. Unfortunately, current treatment options for hypertrophic scars, such as surgery and pressure garments, often fail to prevent their reappearance. One of the primary challenges in treating hypertrophic scars is a lack of knowledge about the molecular mechanisms underlying their formation. In this review, we critically analyze studies that have attempted to uncover the molecular mechanisms behind hypertrophic scar formation after severe burn injuries, as well as clinical trials conducted to treat post-burn hypertrophic scars. We found that most clinical trials used pressure garments, laser treatments, steroids, and proliferative inhibitors for hypertrophic scars, with outcomes measured using subjective scar scales. However, fundamental research using human burn injury biopsies has shown that pathways such as Transforming Growth factor β (TGFβ), Phosphatase and tensin homolog (PTEN), and Toll-like receptors (TLRs) could be potentially regulated to reduce scarring. Therefore, we conclude that more testing is necessary to determine the efficacy of these molecular targets in reducing hypertrophic scarring. Specifically, double-blinded clinical trials are needed, where the outcomes can be measured with more robust quantitative molecular parameters.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.